X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs TEVA PHARMA (Israel) - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON    TEVA PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
TEVA PHARMA
Dec-13
BIOCON /
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1882,882-   
Low Rs3052,503-   
Sales per share (Unadj.) Rs68.71,653.9-  
Earnings per share (Unadj.) Rs7.6103.3-  
Cash flow per share (Unadj.) Rs14.0237.0-  
Dividends per share (Unadj.) Rs1.0090.44-  
Dividend yield (eoy) %0.13.4 4.0%  
Book value per share (Unadj.) Rs86.31,837.1-  
Shares outstanding (eoy) m600.00848.00-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.91.6 667.2%   
Avg P/E ratio x98.926.1 379.3%  
P/CF ratio (eoy) x53.411.4 470.3%  
Price / Book Value ratio x8.61.5 589.9%  
Dividend payout %13.287.5 15.1%   
Avg Mkt Cap Rs m447,9002,283,291 19.6%   
No. of employees `0006.144.9 13.7%   
Total wages/salary Rs m9,3110-   
Avg. sales/employee Rs Th6,705.831,204.3 21.5%   
Avg. wages/employee Rs Th1,514.20-   
Avg. net profit/employee Rs Th736.91,949.3 37.8%   
INCOME DATA
Net Sales Rs m41,2341,402,479 2.9%  
Other income Rs m2,0620-   
Total revenues Rs m43,2961,402,479 3.1%   
Gross profit Rs m8,291384,070 2.2%  
Depreciation Rs m3,851113,364 3.4%   
Interest Rs m61527,547 2.2%   
Profit before tax Rs m5,887243,159 2.4%   
Minority Interest Rs m2131,105 19.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-159,620 0.0%   
Tax Rs m1,569-2,969 -52.9%   
Profit after tax Rs m4,53187,612 5.2%  
Gross profit margin %20.127.4 73.4%  
Effective tax rate %26.7-1.2 -2,183.0%   
Net profit margin %11.06.2 175.9%  
BALANCE SHEET DATA
Current assets Rs m41,486947,229 4.4%   
Current liabilities Rs m21,413826,064 2.6%   
Net working cap to sales %48.78.6 563.5%  
Current ratio x1.91.1 169.0%  
Inventory Days Days6491 70.4%  
Debtors Days Days9496 98.2%  
Net fixed assets Rs m50,661458,080 11.1%   
Share capital Rs m3,0003,452 86.9%   
"Free" reserves Rs m48,8080-   
Net worth Rs m51,8081,557,888 3.3%   
Long term debt Rs m17,898717,118 2.5%   
Total assets Rs m99,8973,205,113 3.1%  
Interest coverage x10.69.8 107.6%   
Debt to equity ratio x0.30.5 75.1%  
Sales to assets ratio x0.40.4 94.3%   
Return on assets %5.23.6 143.4%  
Return on equity %8.75.6 155.5%  
Return on capital %9.64.9 195.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4,7100-   
CASH FLOW
From Operations Rs m6,621223,482 3.0%  
From Investments Rs m-6,840-79,189 8.6%  
From Financial Activity Rs m-2,397-268,082 0.9%  
Net Cashflow Rs m-2,612-123,789 2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.04 Rs / USD

Compare BIOCON With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare BIOCON With: ORCHID PHARMA LTD  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views On News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 22, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS